Verrica Pharmaceuticals Inc (VRCA) Major Shareholder Matt Davidson Sells 13,436 Shares

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 13,436 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $10.37, for a total value of $139,331.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Wednesday, April 24th, Matt Davidson sold 9,203 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $9.92, for a total value of $91,293.76.
  • On Thursday, April 18th, Matt Davidson sold 3,516 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.54, for a total value of $37,058.64.
  • On Tuesday, April 16th, Matt Davidson sold 3,193 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.39, for a total value of $33,175.27.
  • On Thursday, April 11th, Matt Davidson sold 18,850 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.16, for a total value of $191,516.00.
  • On Monday, April 8th, Matt Davidson sold 12,385 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.67, for a total value of $132,147.95.
  • On Tuesday, March 26th, Matt Davidson sold 13,667 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.50, for a total value of $157,170.50.
  • On Thursday, March 21st, Matt Davidson sold 7,920 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.27, for a total value of $97,178.40.
  • On Monday, March 18th, Matt Davidson sold 11,626 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.26, for a total value of $142,534.76.
  • On Wednesday, March 13th, Matt Davidson sold 25,045 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.55, for a total value of $289,269.75.
  • On Friday, March 8th, Matt Davidson sold 20,558 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.72, for a total value of $240,939.76.

Shares of NASDAQ VRCA traded up $0.43 during mid-day trading on Friday, reaching $9.99. 12,600 shares of the company’s stock were exchanged, compared to its average volume of 57,943. The firm has a market cap of $255.02 million and a P/E ratio of -7.09. Verrica Pharmaceuticals Inc has a twelve month low of $6.44 and a twelve month high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Thursday, March 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.03). As a group, analysts anticipate that Verrica Pharmaceuticals Inc will post -1.14 EPS for the current fiscal year.

A number of research firms have recently commented on VRCA. HC Wainwright began coverage on Verrica Pharmaceuticals in a research report on Thursday, February 21st. They set a “buy” rating and a $20.00 price target on the stock. Zacks Investment Research lowered Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 5th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $26.25.

A number of institutional investors have recently made changes to their positions in VRCA. Bank of New York Mellon Corp acquired a new stake in Verrica Pharmaceuticals in the 3rd quarter valued at approximately $195,000. BlackRock Inc. acquired a new stake in Verrica Pharmaceuticals in the 3rd quarter valued at approximately $4,145,000. Kornitzer Capital Management Inc. KS raised its position in Verrica Pharmaceuticals by 46.1% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 215,145 shares of the company’s stock valued at $3,496,000 after buying an additional 67,910 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Verrica Pharmaceuticals during the 3rd quarter worth approximately $1,463,000. Finally, Vanguard Group Inc. increased its position in shares of Verrica Pharmaceuticals by 950.7% during the 3rd quarter. Vanguard Group Inc. now owns 292,489 shares of the company’s stock worth $4,753,000 after purchasing an additional 264,651 shares during the last quarter. 32.86% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/verrica-pharmaceuticals-inc-vrca-major-shareholder-matt-davidson-sells-13436-shares-of-stock.html.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Featured Story: Cost of Capital

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.